STOCK TITAN

Aridis Pharmaceuticals, Inc. - ARDS STOCK NEWS

Welcome to our dedicated page for Aridis Pharmaceuticals news (Ticker: ARDS), a resource for investors and traders seeking the latest updates and insights on Aridis Pharmaceuticals stock.

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) is a biopharmaceutical company based in Los Gatos, California, focused on developing innovative anti-infective therapies for life-threatening infections. The company leverages its proprietary ʎPEX™ and MabIgX® technology platforms to identify potent B-cells from patients who have successfully overcome infections and rapidly manufacture monoclonal antibodies (mAbs) for therapeutic use. These mAbs are already of human origin and do not require further engineering optimization to achieve full functionality.

Aridis is advancing multiple clinical-stage mAbs targeting bacteria and viruses that cause severe infections such as ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP). The company’s novel approach addresses the limitations of current broad-spectrum antibiotics, such as increasing drug resistance, short duration of efficacy, and disruption of the human microbiome.

Highlighted in Aridis' pipeline are seven key products:

  • AR-301 (VAP/HAP/CAP): A fully human IgG1 mAb targeting Staphylococcus aureus alpha-toxin, currently in Phase 3 clinical development.
  • AR-320 (VAP): A fully human mAb for the prevention of VAP caused by S. aureus, in Phase 3 clinical development.
  • AR-501 (Cystic Fibrosis): An inhaled formulation of gallium citrate to treat chronic lung infections in cystic fibrosis patients, in Phase 2a clinical study.
  • AR-701 (COVID-19): A cocktail of fully human mAbs targeting SARS-CoV-2 spike proteins.
  • AR-101 (HAP): A fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11.
  • AR-201 (RSV Infection): A fully human IgG1 mAb directed against the F-protein of respiratory syncytial virus (RSV), licensed to the Serum Institute of India.
  • AR-401 (Blood Stream Infections): A preclinical mAb program targeting gram-negative Acinetobacter baumannii.

Aridis has recently achieved significant milestones including positive Phase 2a results for AR-501, FDA and EMA agreement on AR-301 Phase 3 study design, and multiple grants from the National Institute of Allergy and Infectious Diseases (NIAID). The company continues to explore strategic partnerships to advance its clinical programs and maximize value for shareholders.

News
Rhea-AI Summary

Aridis Pharmaceuticals (OTC: ARDS) provided a corporate update on June 24, 2024, detailing recent developments. The company is in talks with pharmaceutical firms and investors for partnerships and funding to advance its major clinical product candidates: AR-301, AR-320, AR-501, and the APEX platform. AR-301 showed promising results in elderly patients in its Phase 3 trial, despite reduced enrollment due to COVID-19. AR-320's Phase 3 trial for pneumonia prevention is on hold due to a licensing dispute with MedImmune. AR-501 met primary and secondary endpoints in its Phase 2 trial for cystic fibrosis patients. The company has reduced expenses and aims to finalize business objectives and SEC filings soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals, Inc. (ARDS) has announced the adjournment of its 2023 Annual Meeting of Stockholders due to lack of the requisite quorum, rescheduled for January 12, 2024. The company urges stockholders to vote on the proposals set forth in the definitive proxy statement on Schedule 14A. Stockholders as of November 2, 2023, can vote, even if they have sold their shares, and are encouraged to read the proxy materials available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals, Inc. has received two grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH). The grants will be used to develop pan-coronavirus human monoclonal antibodies and antibacterial monoclonal antibodies. The company's COVID-19 monoclonal antibody program showed positive efficacy data in non-human primates. Aridis Pharmaceuticals has also been uplisted to the OTCQB market and raised $2.0 million through the issuance and sale of common stock and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.09%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.41%
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals, Inc. (OTC: ARDS) Announces Pricing of 10 Million Share Offering at $0.20 Per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
none
Rhea-AI Summary
Aridis Pharmaceuticals has received positive feedback from the European Medicines Agency (EMA) regarding its proposed Phase 3 study for AR-301, an investigational monoclonal antibody candidate. The study aims to evaluate the efficacy of AR-301 as an adjunctive therapy for pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients. The EMA has agreed to the study design, including the primary efficacy endpoint of Clinical Cure on Day 21. The magnitude of absolute efficacy was higher in older adults, with a +34% improvement on Day 21 and +38% improvement on Day 28 compared to +11% improvement in the overall population. The EMA also approved the expansion of the study to include ventilated hospital acquired pneumonia and ventilated community acquired pneumonia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.91%
Tags
-
Rhea-AI Summary
Aridis Pharmaceuticals has been granted QIDP designation by the FDA for its AR-301 monoclonal antibody, which is in Phase 3 clinical development as a treatment for pneumonia caused by gram-positive Staphylococcus aureus. This designation provides priority review status and accelerates the drug development and regulatory review processes. The company received positive feedback from the FDA on its proposed Phase 3 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none

FAQ

What is Aridis Pharmaceuticals, Inc. known for?

Aridis Pharmaceuticals, Inc. is known for discovering and developing anti-infective therapies to combat life-threatening infections, focusing on innovative monoclonal antibodies (mAbs).

What are the key products in Aridis' pipeline?

Key products include AR-301 for VAP/HAP/CAP, AR-320 for VAP prevention, AR-501 for cystic fibrosis, AR-701 for COVID-19, AR-101 for HAP, AR-201 for RSV infection, and AR-401 for blood stream infections.

What technology platforms does Aridis use?

Aridis utilizes its proprietary ʎPEX™ and MabIgX® technology platforms to rapidly identify and manufacture potent antibody-producing B-cells for therapeutic use.

What recent achievements has Aridis Pharmaceuticals accomplished?

Recent achievements include positive Phase 2a results for AR-501, FDA and EMA agreement on AR-301 Phase 3 study design, and receiving multiple NIH grants for developing new mAbs.

What is the focus of Aridis' clinical programs?

Aridis focuses on developing monoclonal antibodies to treat severe bacterial and viral infections, targeting drug-resistant strains and overcoming the limitations of broad-spectrum antibiotics.

Where is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is headquartered in Los Gatos, California, USA.

How does Aridis Pharmaceuticals address antimicrobial resistance?

Aridis targets drug-resistant bacteria and viruses with innovative mAbs that harness the human immune system, offering a therapeutic approach distinct from broad-spectrum antibiotics.

What are the strategic goals of Aridis Pharmaceuticals?

Aridis aims to advance its clinical programs through partnerships, optimize therapeutic efficacy, and address unmet medical needs in infections with high mortality rates.

Who are the collaborators and partners of Aridis Pharmaceuticals?

Aridis collaborates with organizations like the Cystic Fibrosis Foundation and has licensing agreements with entities like the Serum Institute of India.

What is AR-301 and what infections does it target?

AR-301 is a fully human IgG1 mAb targeting S. aureus alpha-toxin, developed as an adjunctive therapy for ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), and community-acquired pneumonia (CAP).

Aridis Pharmaceuticals, Inc.

OTC:ARDS

ARDS Rankings

ARDS Stock Data

2.23M
37.40M
14.84%
10.38%
5.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Los Gatos